NYSE American - Delayed Quote • USD
Protalix BioTherapeutics, Inc. (PLX)
At close: April 23 at 4:00 PM EDT
After hours: April 23 at 4:03 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 1 | 1 |
Avg. Estimate | -0.02 | -0.02 | 0.21 | 0.81 |
Low Estimate | -0.02 | -0.02 | 0.21 | 0.81 |
High Estimate | -0.02 | -0.02 | 0.21 | 0.81 |
Year Ago EPS | -0.07 | 0.21 | 0.09 | 0.21 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 1 | 1 |
Avg. Estimate | 9.2M | 8.9M | 74.06M | 127.35M |
Low Estimate | 9.2M | 8.9M | 74.06M | 127.35M |
High Estimate | 9.2M | 8.9M | 74.06M | 127.35M |
Year Ago Sales | -- | 35.08M | 65.49M | 74.06M |
Sales Growth (year/est) | -- | -74.60% | 13.10% | 72.00% |
Earnings History
CURRENCY IN USD | 12/31/2022 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.15 | -0.04 | -0.07 | -0.03 |
EPS Actual | -0.07 | 0.21 | -0.04 | -0.07 |
Difference | 0.08 | 0.25 | 0.03 | -0.04 |
Surprise % | 53.30% | 625.00% | 42.90% | -133.30% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.02 | -0.02 | 0.21 | 0.81 |
7 Days Ago | -0.02 | -0.02 | 0.21 | 0.81 |
30 Days Ago | -0.02 | -0.02 | 0.14 | 0.81 |
60 Days Ago | -0.02 | -0.02 | 0.14 | 0.81 |
90 Days Ago | -0.02 | -0.02 | 0.14 | 0.81 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | PLX | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 71.40% | -- | -- | 0.40% |
Next Qtr. | -109.50% | -- | -- | 9.90% |
Current Year | 133.30% | -- | -- | 4.30% |
Next Year | 285.70% | -- | -- | 13.40% |
Next 5 Years (per annum) | 25.00% | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | HC Wainwright & Co.: Buy to Buy | 11/14/2023 |
Maintains | HC Wainwright & Co.: Buy to Buy | 10/31/2023 |
Related Tickers
BLRX BioLineRx Ltd.
0.6368
-5.95%
LXRX Lexicon Pharmaceuticals, Inc.
1.6100
-5.85%
CANF Can-Fite BioPharma Ltd.
1.9700
-0.51%
MCRB Seres Therapeutics, Inc.
0.7600
+21.68%
ARDX Ardelyx, Inc.
6.39
-1.84%
CDTX Cidara Therapeutics, Inc.
0.5125
-0.27%
OCUP Ocuphire Pharma, Inc.
1.5400
+1.99%
FBIO Fortress Biotech, Inc.
1.8100
+3.43%
GTHX G1 Therapeutics, Inc.
4.1900
+2.20%
RVPH Reviva Pharmaceuticals Holdings, Inc.
3.0600
-0.97%